Becton Dickinson & Co. closed 9.83% short of its 52-week high of $251.99, which the company reached on February 3rd.

American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic ...

Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and ...

Becton Dickinson & Co. closed 2.75% below its 52-week high of $251.99, which the company reached on February 3rd.

Becton Dickinson (BDX) rose 2.4% in premarket trading as reports surface of potential separation of its $30 billion life ...

At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...

Becton Dickinson (BDX) delivered earnings and revenue surprises of 15.10% and 1.32%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

BofA analyst Travis Steed raised the firm’s price target on Becton Dickinson (BDX) to $269 from $265 and keeps a Buy rating on the shares after ...

While the top- and bottom-line numbers for Becton Dickinson (BDX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key ...

Becton Dickinson beat expectations for first-quarter results and said its board has authorized a plan to separate its biosciences and diagnostic solutions unit on Wednesday, as the medical device ...

Becton Dickinson plans to spin off its Biosciences and Diagnostic Solutions unit, targeting a fiscal 2026 completion, while updating FY25 revenue guidance.

Becton Dickinson shares have climbed 8% since the beginning of the year, while the S&P's 500 index has increased 27%. In the final minutes of trading on Wednesday, shares hit $245.06, a rise of 4% in ...